tradingkey.logo
tradingkey.logo
Search

Puretech Presents New Data From Phase 2b Open-Label Extension Study Of Deupirfenidone

ReutersSep 29, 2025 7:48 AM
facebooktwitterlinkedin
View all comments0

- PureTech Health PLC PRTC.L:

  • PURETECH PRESENTS NEW DATA FROM PHASE 2B OPEN-LABEL EXTENSION STUDY OF DEUPIRFENIDONE (LYT-100), FURTHER SUPPORTING STRONG AND DURABLE EFFICACY AND POTENTIAL TO SERVE AS NEW STANDARD OF CARE IN IPF

  • PURETECH HEALTH PLC - PATIENTS SWITCHING TO DEUPIRFENIDONE ACHIEVED LUNG FUNCTION STABILIZATION WITH FAVORABLE TOLERABILITY

  • PURETECH HEALTH PLC - PHASE 3 TRIAL DESIGN UPDATE EXPECTED Q4 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI